Amgen and the THRIVE Trial: Key Data on Veligrotug for Thyroid Eye Disease

Saturday, 14 September 2024, 10:40

Amgen highlights significant findings from the Viridian THRIVE trial, which evaluated veligrotug for thyroid eye disease. The trial's positive topline data revealed impressive efficacy and safety profiles. Veligrotug demonstrated remarkable results in reducing proptosis and improving diplopia symptoms.
Ophthalmologytimes
Amgen and the THRIVE Trial: Key Data on Veligrotug for Thyroid Eye Disease

Amgen's Focus on Veligrotug in Thyroid Eye Disease

Amgen has revealed groundbreaking results from the THRIVE clinical trial conducted by Viridian Therapeutics, assessing the effects of veligrotug in patients with active thyroid eye disease (TED). This phase 3 trial involved 113 participants, among whom 75 received veligrotug, while the remainder were given a placebo.

Impressive Efficacy Results

  • The study exhibited a 70% proptosis responder rate for veligrotug compared to just 5% for placebo.
  • Patients on veligrotug showed a mean proptosis reduction of 2.9 mm, surpassing the 0.5 mm reduction seen in the placebo group.
  • Major improvements in diplopia resolution were reported in 54% of veligrotug patients, contrasting sharply with 12% in the placebo cohort.

Safety Profile and Next Steps

According to Michael Yen, MD, the safety profile of veligrotug was generally favorable, with mild adverse events and a low discontinuation rate. The ongoing phase 3 THRIVE-2 trial is expected to yield further insights by the end of 2024, while Amgen plans to submit a Biologics License Application for veligrotug in late 2025.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest insights and trends from around the world. Stay informed and elevate your global perspective effortlessly.

Subscribe